公开(公告)号：WO2022186708A1

公开(公告)日：2022-09-09

申请号：PCT/PT2022/050010

申请日：2022-03-04

Applicant: INSTITUTO SUPERIOR TÉCNICO ,  INSTITUTO DE MEDICINA MOLECULAR ,  FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA

Inventor： CARREIRA, João Manuel Coelho ,  HENRIQUE, Domingos Manuel Pinto ,  DIOGO, Maria Margarida Fonseca Rodrigues ,  RODRIGUES, Carlos André Vitorino ,  MIRANDA, Cláudia Daniela Canelas

IPC: C12N5/074 ,  C12N15/10 ,  C12N15/87

Abstract: A presente divulgação descreve um método para a edição do genoma de células estaminais, assim como uma cassete genética que compreende pelo menos um promotor, um marcador, e um nulómero, em que o marcador compreende pelo menos um gene codificador de uma proteína de fluorescência, de resistência a antibiótico, de sensibilidade a drogas, ou suas combinações; e em que o nulómero é clivável por pelo menos um sistema de nucleases de edição genómica, de preferência o sistema de repetições palindrómicas curtas agrupadas e regularmente interespaçadas, o dedo de zinco, nucleases efetoras semelhantes a ativadores de transcrição (TALENs), ou as suas misturas.

公开(公告)号：WO2021201710A1

公开(公告)日：2021-10-07

申请号：PCT/PT2021/050011

申请日：2021-04-01

Applicant: INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES ,  UNIVERSIDADE DE COIMBRA ,  FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA

Inventor： DE OLIVEIRA DIÓGENES NOGUEIRA, Maria José ,  FONSECA GOMES, João Filipe ,  SANTOS, André Jerónimo ,  FERREIRA DE SOUSA SEBASTIÃO, Ana Maria ,  BANDEIRA DUARTE, Carlos

IPC: A61K38/17 ,  A61P25/28 ,  G01N33/50 ,  A61K38/179 ,  C07K14/70571 ,  C12N9/12 ,  C12Y207/10 ,  G01N2800/52 ,  G01N33/6896

Abstract: Therapeutic Agents, Pharmaceutical Compositions, and Associated Biomarkers The invention relates to the identification of pharmaceutical compositions, therapeutic agents, peptides, nucleic acids, genetic constructs, vectors, cells, and medicaments, and their use in methods of treatment. For example, the treatment of neuropathological conditions, in particular Alzheimer's disease. Furthermore, provided herein are biomarkers, methods for their use, methods of diagnosis, methods of monitoring disease progression, and methods for monitoring medicament efficacy, in particular for Alzheimer's disease.

公开(公告)号：WO2007101710A1

公开(公告)日：2007-09-13

申请号：PCT/EP2007/002110

申请日：2007-03-09

Applicant: CENIX BIOSCIENCE GMBH ,  INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA ,  HANNUS, Michael ,  MARTIN, Cecilie ,  MOTA, Maria, M. ,  PRUDENCIO, Miguel ,  RODRIGUES, Christina, Dias

Inventor： HANNUS, Michael ,  MARTIN, Cecilie ,  MOTA, Maria, M. ,  PRUDENCIO, Miguel ,  RODRIGUES, Christina, Dias

IPC: A61K31/15 ,  A61K31/536 ,  A61K31/17 ,  A61K31/165 ,  A61K31/397 ,  A61K31/49 ,  A61K31/4706 ,  A61K31/155 ,  A61K31/505 ,  A61K31/122 ,  A61K31/65 ,  A61K31/35 ,  A61K31/137 ,  G01N33/50 ,  A61P33/06

CPC classification number: G01N33/5047 ,  A61K31/122 ,  A61K31/137 ,  A61K31/15 ,  A61K31/155 ,  A61K31/165 ,  A61K31/17 ,  A61K31/35 ,  A61K31/397 ,  A61K31/4706 ,  A61K31/49 ,  A61K31/505 ,  A61K31/536 ,  A61K31/65 ,  G01N33/5067 ,  G01N33/56905 ,  G01N2333/445 ,  G01N2500/00 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  A61K2300/00

Abstract: The present invention relates to the use of inhibitors of scavenger receptor class proteins, in particular ScarB1 for the production of a medicament for treatment of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.

Abstract translation: 本发明涉及清道夫受体类蛋白质抑制剂，特别是ScarB1在制备用于治疗和/或预防感染的药物中的应用，涉及肝细胞和/或造血细胞，特别是疟疾。

公开(公告)号：WO2010049173A1

公开(公告)日：2010-05-06

申请号：PCT/EP2009/007793

申请日：2009-10-30

Applicant: CENIX BIOSCIENCE GMBH ,  INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA ,  HANNUS, Michael ,  MARTIN, Cecilie ,  MOTA, Maria, M. ,  PRUDENCIO, Miguel ,  RODRIGUES, Christina, Dias

Inventor： HANNUS, Michael ,  MARTIN, Cecilie ,  MOTA, Maria, M. ,  PRUDENCIO, Miguel ,  RODRIGUES, Christina, Dias

IPC: A61K38/00 ,  C12N15/113

CPC classification number: A61K38/10 ,  A61K31/496 ,  A61K45/06 ,  C12N15/1137 ,  C12N2310/14 ,  C12Y207/11001 ,  C12Y207/11013 ,  Y02A50/409 ,  Y02A50/411 ,  Y02A50/414 ,  A61K2300/00

Abstract: The present invention relates to the use of inhibitors of host kinases for the production of a medicament for therapy of and/or prophylaxis against infections, involving liver cells and/or hematopoietic cells, in particular malaria.

Abstract translation: 本发明涉及宿主激酶抑制剂在制备用于治疗和/或预防感染的药物中的用途，涉及肝细胞和/或造血细胞，特别是疟疾。

公开(公告)号：WO2021064165A1

公开(公告)日：2021-04-08

申请号：PCT/EP2020/077642

申请日：2020-10-02

Applicant: UNIVERSITAT DE BARCELONA ,  UNIVERSITAT POMPEU FABRA ,  UNIVERSITAT AUTÒNOMA DE BARCELONA ,  INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES ,  FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA

Inventor： CASADÓ BURILLO, Vicent ,  MORENO GUILLÉN, Estefania ,  MALDONADO LÓPEZ, Rafael ,  ANDREU MARTÍNEZ, David ,  GALLO, María ,  PARDO CARRASCO, Leonardo ,  CASTANHO, Miguel ,  NEVES, Vera ,  CAVACO, Marco

IPC: C07K7/08 ,  A61P25/00 ,  A61K38/00

Abstract: The present invention relates to compounds of formula (I): AA1-AA2-D-Ile-AA3-D-Met-D-Tyr-D-Ala-D-Tyr-D-Val-D-Ala-Gly-D-Ile-D-Leu-D-Lys-D-Arg-D-Trp-NH2 or a pharmaceutically acceptable salts thereof, to processes for their obtention and to their therapeutic indications.

公开(公告)号：WO2021191464A1

公开(公告)日：2021-09-30

申请号：PCT/EP2021/058146

申请日：2021-03-29

Applicant: INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES ,  FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA

Inventor： LABÃO ALPIARÇA SOUSA DE ALMEIDA, Carlos Diogo ,  LOPES BERNARDES, Gonçalo José

IPC: A61K45/06 ,  A61K47/64 ,  A61P35/00 ,  A61K47/643

Abstract: The present invention in various aspects and embodiments involves the use of CO releasing molecules, such as conjugates comprising tumour-selective ligands and groups capable of releasing carbon monoxide (CO), for exerting immunomodulatory effects in cancer treatment, such as reductions in the expression of immune checkpoint molecules and the level of inhibitory macrophages. This can reduce immunosuppression in tumour tissue and can be useful, for example, in the treatment of immunosuppressive cancers or the treatment of cancers in combination with cancer immunotherapy.

公开(公告)号：WO2021156451A1

公开(公告)日：2021-08-12

申请号：PCT/EP2021/052829

申请日：2021-02-05

Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ,  UNIVERSITÉ DE PARIS ,  FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA ,  INSTITUTO DE MEDICINA MOLECULAR JOÃO LOBO ANTUNES ,  UNIVERSITAT POMPEU FABRA

Inventor： MAMMANO, Fabrizio ,  TAUZIN, Alexandra ,  CASTANHO, Miguel ,  VEIGA, Ana Salome ,  COUTO, Carla Iris ,  FREIRE, Joao ,  ANDREU MARTINEZ, David ,  PEREZ-PEINADO, Clara ,  VALLE GARCIA, Javier ,  GONCALVES, Joao

IPC: A61P31/18 ,  A61K38/00 ,  C07K14/825

Abstract: The present inventors have discovered a protease-resistant peptide fragment (termed pepRF1) of the Dengue virus capsid protein that is a potent antagonist of C-X-C motif chemokine receptor 4 (CXCR4). This peptide fragment may be useful, for example, in the treatment of CXCR4 mediated conditions, such as HIV and cancer. Thus, the present invention relates to a pepRF1 peptide consisting of the amino acid 10 sequence of SEQ ID NO: 3. The pepRF1 peptide may consist of residues 66 to 82 of the capsid protein of Dengue virus 2, 1 or 3; or residues 65 to 81 of the Dengue virus 2 capsid protein; or the corresponding residues in another Dengue virus capsid protein. For example, the pepRF1 peptide may consist of any one of SEQ ID NOs: 10 to 14.